Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection:is elimination possible in a high-prevalence setting? by Gountas, Ilias et al.
                          Gountas, I., Sypsa, V., Anagnostou, O., Martin, N., Vickerman, P.,
Kafetzopoulos, E., & Hatzakis, A. (2017). Treatment and primary prevention
in people who inject drugs for chronic hepatitis C infection: is elimination
possible in a high-prevalence setting? Addiction, 112(7), 1290-1299.
https://doi.org/10.1111/add.13764
Peer reviewed version
Link to published version (if available):
10.1111/add.13764
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Soc. for Study of addiction at https://onlinelibrary.wiley.com/doi/abs/10.1111/add.13764. Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
 
 
 1 
Treatment and primary prevention in people who inject drugs (PWID) for Chronic 
Hepatitis C (CHC): Is elimination possible in a high prevalence setting? 
Gountas I.1, Sypsa V.1, Anagnostou O.2, Martin N.K3,4, Vickerman P.4, Kafetzopoulos 
E.2, Hatzakis A.1 
1Department of Hygiene, Epidemiology & Medical Statistics, Athens University 
Medical School, Athens, Greece. 
2 Organization Against Drugs (OKANA), Athens, Greece. 
3 Division of Global Public Health, University of California, San Diego, USA 
4 School of Social and Community Medicine, University of Bristol, Bristol 
 
 Running head: HCV elimination among PWID in Athens 
Word count:  4116 
 
Corresponding author:  
Vana Sypsa 
Assistant Professor of Epidemiology and Preventive Medicine 
Dept. of Hygiene, Epidemiology and Medical Statistics 
Medical School 
National and Kapodistrian University of Athens 
Tel.: (30) 210 7462193 
email: vsipsa@med.uoa.gr 
 
 
 
 
 2 
 
Conflict of interest:  
IG:  No conflict of interest 
VS: Receipt of honoraria or consultation fees: Gilead and Abbvie 
OA:  No conflict of interest 
NM: Received research grants from Gilead, and honoraria from Merck, Abbvie, and 
Janssen 
PV: Received grants from Gilead. 
EK:  No conflict of interest 
AH: Receipt of grants/research support: Gilead, Novartis, Co-Chair of Hepatitis B and 
C Public Policy Association funded by Gilead, Abbvie, BMS. Receipt of honoraria or 
consultation fees: Gilead, BMS.  
 
 
 
 3 
Abstract 
Aims:  To project the impact of scaling up oral antiviral therapy and harm reduction 
on chronic hepatitis C (CHC) prevalence and incidence among people who inject 
drugs (PWID) in Greece, to estimate the relationship between required treatment 
levels and expansion of harm reduction programs to achieve specific targets and to 
examine whether HCV elimination among PWID is possible in this high prevalence 
setting. 
Design:  A dynamic discrete time, stochastic individual-based model was developed 
to simulate HCV transmission among PWID incorporating the effect of HCV 
treatment and harm reduction strategies, and allowing for reinfection following 
treatment. 
Setting/Participants: The population of 8,300 PWID in Athens Metropolitan area 
Measurements: Reduction in HCV prevalence and incidence in 2030 compared to 
2016. 
Findings: Moderate expansion of HCV treatment (treating 4%-8% of PWID/year), 
with simultaneous increase of 2%/year in harm reduction coverage (from 44% to 
72% coverage over 15 years), was projected to reduce CHC prevalence among PWID 
in Athens by 46%-90% in 2030, compared to 2016. CHC prevalence would reduce 
below 10% within the next 4-5 years if annual HCV treatment numbers were 
increased up to 16%-20% PWID/year. The effect of harm reduction on incidence was 
more pronounced under lower treatment rates. 
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Conclusions: Based on theoretical model projections, scale-up HCV treatment and 
harm reduction could achieve major reductions in HCV incidence and prevalence 
among PWID in Athens until 2030. Fast track elimination of CHC in the next 4-5 years 
is possible by increasing the number of treated PWID to more than 16% of PWID per 
year combined with moderate increases in harm reduction coverage. 
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Introduction 
Hepatitis C (HCV) virus affects about 170 million persons (3% of world population) 
worldwide (1). In the developed world, mortality attributed to HCV is higher than HIV 
(2, 3) and the most common route of transmission is unsafe injection of drugs e.g. 
receptive sharing (4, 5). It is estimated that around 10 million or 60% of people who 
inject drugs (PWID) have been infected by HCV worldwide (6). Harm reduction 
strategies such as high-coverage needle and syringe programs (HCNSP) and opiate 
substitution therapy (OST) have been often used to prevent the spread of HCV 
among PWID. Empirical studies have shown that these interventions can 
substantially reduce the risk of HCV virus acquisition among PWID (7, 8), but 
modeling work has shown they have slow impact on the reduction of HCV 
prevalence if not combined with antiviral therapy (9, 10).  
Over recent years, significant developments in the treatment of chronic hepatitis C 
(CHC) have occurred. New therapeutic regimens targeting specific HCV genome 
regions have been developed (direct acting antivirals [DAAs]). These therapies offer 
higher efficacy (sustained virological response (SVR) ≥90%), shorter duration and 
simplified dosing in contrast to the traditional therapies involving pegylated 
interferon with ribavirin (11, 12). Due to these recent clinical advances, HCV has now 
become curable in the great majority of cases. The concept of using HCV treatment 
for preventing onward transmission (treatment as prevention [TasP]) to achieve the 
goal of HCV elimination is under discussion. Recently, WHO released the Global 
Health Sector Strategy on viral hepatitis targeting elimination by 2030 (13).  
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Mathematical modeling studies have shown that HCV treatment for PWID could be 
an effective and cost-effective strategy to reduce CHC prevalence and incidence 
among PWID (14-19). More specifically, treating PWID could be a more cost-effective 
strategy than treating ex- or non- PWID, due to prevention of secondary infections, if 
chronic CHC prevalence among PWID is less than 60% (15). Non treatment-based 
prevention strategies (like OST and HCNSP), coupled with antiviral therapy, could 
contribute significantly to decreasing CHC prevalence and incidence (20). 
Prior to 2002, guidelines in the US recommended against treating active PWID due to 
considerations about treatment adherence and the possibility of re-infection (21). 
Recent studies have shown that PWID, under Peg-IFN+RBV therapy, exhibit similar 
SVR compared to non-PWID (22-24), and have low rates of re-infection (1-5% per 
year) (25-28). Revised guidelines for HCV now recommend treatment for PWID (29), 
and new European guidelines on treatment recommend prioritizing DAA therapy for 
those with an ongoing risk of transmission (30).  
Athens faces serious public health problems among PWID. Apart from the HIV 
outbreak in 2011 (31-33), the anti-HCV prevalence among PWID was 80% in 2014 
(34). A substantial increase in the burden of CHC is anticipated to occur in the next 
15-20 years (35). Treatment could be an effective way to inhibit the continuing 
transmission in this population. 
The aims of this study were to: 1) Estimate the potential impact of scaling up rates of 
HCV DAA treatment and harm reduction strategies on CHC prevalence and incidence 
among PWID in Athens until 2030; 2) Estimate the degree to which scaling up harm 
reduction strategies reduces the required CHC treatment levels needed to achieve a 
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specified impact on HCV prevalence and incidence; and 3) Assess if HCV elimination 
among PWID is a feasible goal in Athens over the next few years. 
 
Methods  
Design of the Mathematical Model 
In infectious disease epidemiology, mathematical models are a common way to 
explain the spread of diseases, to highlight the key factors that influence the course 
of infection, to predict the impact of potential intervention policies and to help 
inform public health interventions. In those models the population is stratified into 
compartments corresponding to different states of the infection process 
(susceptible, infected, recovered, etc.) and individuals are assumed to move 
between states according to annual transition rates. The impact of various 
interventions can be simulated by modifying these rates, e.g. the effect of harm 
reduction can be simulated by reducing the probability of a PWID becoming infected. 
More details about the methodology and the application of mathematical modeling 
could be found elsewhere (36). 
  
Description of the Mathematical Model 
A discrete time, stochastic, individual based model of HCV transmission among PWID 
was developed in C++ (v.5.6.3) and parameterized to data from Athens (Table 1), 
with the model structure shown in Figure 1. The model describes the transitions 
between four groups of PWID: susceptible people including those who either never 
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been HCV infected, have cleared infection or have had successful treatment; HCV 
chronically infected untreated individuals; patients who failed HCV treatment; and 
PWID being currently treated. The PWID population was additionally stratified 
according to risk of infection (high or low-risk), and whether the person participates 
in harm reduction programmes, i.e. on OST and/or HCNSP (Yes/No). Individuals 
could transition between risk states and on/off harm reduction. We defined as high-
risk those PWID who experience unstable housing, as homelessness is a risk factor 
for HIV infection in this population and both HIV and HCV are spread through 
injecting drug use (31). The transition from low-risk to high-risk was balanced so that 
the proportion of PWID in the high-risk group remained constant over time.   
Every year, PWID enter in the susceptible group at rate θ and exit the various states 
through death (μ1) or cessation of drug use (μ2), equal to the entry rate to keep the 
population size at constant levels. The force of infection for susceptible PWID 
depends on HCV prevalence and whether they are high-risk, participates in harm 
reduction programmes, or both. In that case, the force of infection is multiplied by a 
factor Ζ, Π and ΖΠ (7, 31), respectively. Initially, new injectors are not participating in 
harm reduction programs.  
After infection, PWID have a probability of spontaneously clearing the disease and 
are then at risk of re-infection; to be conservative we assumed that the risk of re-
infection was equal to the initial infection rate. Those who do not clear the infection 
progress to the chronically infected stage. Every year, a fixed number of PWID (Θ(t)) 
are treated. If the number of chronic infections is lower than Θ(t) then all PWID 
receive treatment. We assumed that the probability of treatment depends on 
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whether the patient participates in a harm reduction programme or not, i.e. PWID 
who participate in OST or HCNSP have higher probability of initiating therapy with 
DAAs that those who do not. In the evaluated scenarios with high treatment 
coverage, if the number of available treatments exceeded the number of previously 
untreated PWID participating in harm reduction programmes, then it was assumed 
that they were allocated to PWID who were not in harm reduction programmes.  
If PWID achieve SVR, then they become susceptible again and are at risk of re-
infection, (assuming risk of re-infection equal to the initial infection rate). Otherwise, 
they progress to the chronically infected non-SVR component of the model. PWID in 
this group are assumed to be infectious and are not allowed to be re-treated.  
The model was run until it achieved steady state, which is the level of prevalence in 
the population of PWID in Athens without use of treatment, by varying the infection 
rate. Due to the small proportion (<5‰) of PWID who have been treated for CHC in 
Greece, and for simplicity reasons, we assumed that the treatment rate before 2016 
was negligible. After reaching steady state, we examined intervention scenarios 
involving scaled up treatment coverage and/or increased proportions of PWID on 
harm reduction programmes, and assessed their impact on CHC prevalence. We 
have also assessed under which intervention strategies HCV elimination is possible, 
which we define as reaching a prevalence of chronic HCV of less than 10% or 
reducing incidence by 90%. 
For each scenario, 1000 runs were performed and the results were summarized. In 
order to include the appropriate uncertainty (stochastic variability), the 2.5 and 97.5 
percentiles of the simulations were also shown. 
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Model parameterization 
The total population size of PWID in Athens in 2015 is about 8300 individuals (Table 
1) (34). HCV antibody prevalence among PWID in Athens was 80% in 2014 (34). 
Assuming that 20% of the infected individuals spontaneously clear the infection (37), 
the corresponding prevalence of chronic hepatitis was 64%. We accounted for the 
increased mortality among PWID by firstly assuming that the majority of PWID are 
between 15 and 44 years old, which have an annual death rate according to the 
United Nations Statistics Division for the Greek population of 1% (38). Then a 
standardized mortality ratio of 2 was applied (39), resulting in an estimated 2% 
annual death rate among PWID. The average duration of injecting till cessation was 
assumed to be 12 years (31, 32).  
The proportion of PWID in the high-risk group, i.e. those experiencing unstable 
housing, is estimated to be 23% in Athens (32). In our projections, we have assumed 
that this proportion remained constant over time. In 2013, 44% of PWID participated 
in harm reduction programmes (26% in OST, 15% in HCNSP and 3% in both (32)). In 
Greece, harm reduction programmes include maintenance programmes, where OST 
delivery can be provided indefinitely, meaning that PWID may stay under 
substitution indefinitely. The Greek Organization Against Drugs aims at expanding 
OST programs in Greece by 2% each year from 2015 to achieve the goal of 75% OST 
coverage by 2030. 
We assumed that IFN-free DAAs have 90% SVR until 2017 and 95% in subsequent 
years with a treatment duration of 12 weeks (40), irrespective of genotype (41-43). 
Assuming that PWID who participate in OST or HCNSP have a higher probability of 
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initiating DAA therapy than those that do not, we hypothesized that the proportion 
of annual treatments delivered in the two groups are 66.6% and 33.3%, respectively. 
The impact of this assumption was evaluated in the sensitivity analysis. 
 
Estimation of the relationship between the required treatment coverage and 
expansion of harm reduction programmes to achieve specific targets in CHC 
prevalence 
Through the model, we estimated the required treatment coverage needed to 
reduce CHC prevalence or HCV incidence among PWID by 50%, 75% or 85% by 2030 
assuming either harm reduction coverage levels similar to 2016 (44%) or an increase 
to 60% or 70% coverage from 2017 onwards.  Then a linear regression analysis was 
used to estimate the relationship between the required treatments and harm 
reduction to achieve specific targets in CHC prevalence or incidence. This regression 
relationship was used to estimate the reduction in the number of required 
treatments for increases in harm reduction coverage.  
 
Sensitivity analysis 
To examine the impact of different model assumptions, we undertook a univariate 
sensitivity analysis on the anticipated CHC prevalence achieved in 2030 for the 
intervention scenario that assumed 332 annual CHC treatments (4% of PWID). We 
explored the impact of shorter/longer average duration of injecting carrier (6 or 18 
versus 12 years), lower or higher SVR under treatment with DAAs (80%/100% vs. 
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95%), greater or lesser difference in risk between PWID in harm reduction 
programmes vs. those who are not (0.2/0.8 vs. 0.41), greater difference in risk 
between PWID in the high-risk group vs. those in the low-risk group (5 times higher 
relative risk vs. 2.3), longer duration in the high-risk group (10 years vs. 12 months), 
equal/unequal allocation of treatments among those engaging in harm reduction 
prorgammes vs. those who do not (50%/50%, 80%/20% vs. 66%/33%), the influence 
of changes in  risk behavior after successful treatment (50% lower/higher probability 
of re-infection vs. no change in risk behavior), shorter duration in harm reduction 
programmes (12 months vs. always), and the impact of delaying the interventions by 
3 years (2019 vs. 2016). 
 
Results 
Baseline annual HCV incidence and number of CHC among PWID in Athens  
From the model, it was estimated that about 700 PWID are newly infected with HCV 
in Athens in 2015 (annual incidence: 22.7 (17.3, 27.4) new HCV infections per 100 
person-years). Concerning the prevalent number of PWID with CHC, we estimate 
that there are 5312 PWID with CHC in Athens in 2015 (based on the estimate of 80% 
anti-HCV prevalence and that 80% are viremic).  
Model projections under various scenarios concerning annual treatment coverage 
Figure 2a shows the reduction in CHC prevalence over time for different annual 
treatment rates and assuming a simultaneous annual increase of 2% in harm 
reduction programmes coverage (from 44% in 2015 to 72% in 2030). Moderate 
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expansion in treatment levels, i.e. treating 166 PWID /year (2% of PWID) or 332 
PWID /year (4% of PWID), results in a relative reduction in CHC prevalence of 26.5% 
(18.6%-31.5%) and 46.2% (38.7%-53.8%) in 2030, respectively, compared to 2016 
(CHC prevalence of 64%). When the number of antiviral treatments/year was 
increased to 664 PWID /year (8% of PWID), the projected CHC prevalence in 2030 
would fall by almost 94.8% (92.3%-97.0%). To reduce CHC prevalence to less than 
10% in the next 4-5 years, DAAs should be administered to more than 1370 PWID 
/year (16% of PWID). More specifically, treating 1370 PWID /year (16% of PWID) or 
1660 PWID /year (20% of PWID) would reduce the prevalence below 10% (more than 
85% relative reduction) by 2021 and 2020, respectively.  
Annual HCV incidence would be reduced by 88% (75.5%-97%) in 2030 if more than 
664 PWID received treatment per year. Under moderate treatment coverage i.e. 
treating 166 PWID/year or 332 PWID/year, the annual incidence would be reduced 
by 14% (1%-34%) and 21% (1%-42%) in 2030 compared to 2015, respectively (Figure 
2b). 
Model projections under various scenarios concerning harm reduction 
programmes 
Figure 3 shows the contribution of harm reduction programmes in reducing CHC 
prevalence and incidence among PWID, coupled with antiviral therapy. Under 
moderate treatment coverage (332 PWID/year), an increase of harm reduction 
coverage of 2%/year would contribute an additional 5.1% (1.5%, 11.7%) absolute 
decrease in CHC prevalence and 19.2% (1%, 42.8%) lower incidence in 2030 
compared to constant harm reduction coverage levels. 
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Under high treatment coverage (664 PWID/year), an increase in harm reduction 
coverage of 2% every year would contribute an additional 1% (0.3%, 4.2%) absolute 
decrease in CHC prevalence and 38% (5%, 71.1%) lower incidence in 2030 compared 
to constant harm reduction coverage levels. Thus, under aggressive HCV antiviral 
treatments strategies (1370 PWID/year), the added contribution of harm reduction 
in reducing prevalence is minimal. However, it has a significant impact in the 
reduction of HCV incidence. 
Coverage of treatment and harm reduction to reach fixed targets concerning CHC 
prevalence  
A reduction in CHC prevalence or HCV incidence could be reached either by 
increasing treatment coverage, or harm reduction coverage, or both. Using a 
combined intervention, the necessary number of treatments for reaching specific 
targets in CHC prevalence or HCV incidence could be reduced.  
The relationship between the annual treatment rates needed to reach a specific 
target in CHC prevalence and harm reduction coverage is approximately linear 
(within the range of 44%-70% harm reduction coverage): for example, from the 
model we have estimated that in order to halve CHC prevalence by 2030, the 
required antiviral treatment rate is 5%, 4.25% and 3.8% per year assuming a harm 
reduction coverage of 44% or immediate increase to 60% and 70% coverage, 
respectively. Using linear regression, it was estimated that, increasing the coverage 
of harm reduction by 10% reduces the required annual HCV treatment rate by about 
0.46% (N=40 less HCV treatments per year) (Figure 4a) for halving prevalence by 
2030. Similar results were found for the goal of a 75% reduction or decreasing CHC 
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prevalence to less than 10% by 2030. No significant changes in the required 
treatment rates were observed if the target is to reduce CHC prevalence to less than 
10% in the next five years (data not shown). 
The impact of harm reduction programmes was more pronounced for reducing 
incidence than CHC prevalence. Linear regression suggests that increasing the 
coverage of harm reduction by 10% would reduce the required annual HCV 
treatment rate by about 0.73% (N=60 less HCV treatments per year) (Figure 4b). 
Sensitivity analysis 
The sensitivity analysis shows that the variation in the average injecting duration 
substantially affected the forecasted impact of treatment on CHC prevalence in 2030 
(Figure 5). Specifically, for shorter injecting duration (6 years instead of 12 years) the 
intervention impact decreased relatively by 24% while for longer injection duration 
(18 years instead of 12 years) impact increased by 17%. 
Furthermore, potential changes in the risk behavior following successful treatment 
also affected the predictions of the model. Specifically, if risk behavior halved after 
treatment, the potential impact increased by 38.3% compared to the base case. 
Conversely, if the risk of infection increased after treatment - e.g. due to 
complacency caused by improvements in antiviral therapy - the anticipated impact 
was be 18.7% lower than the base case. Decreasing the duration of harm reduction 
programmes to 12 months, results in 14.7% lower impact of the intervention (Figure 
5, Figure S1). 
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Delaying the initiation of the intervention (i.e. scale-up of treatment and harm 
reduction coverage) by 3 years resulted in 11.8% less impact. Variability in SVR also 
affected the intervention’s impact - if the SVR of DAAs was 80% (95% in base case), 
the estimated intervention impact would be 10% lower, whereas if SVR was 100%, 
the impact would increase by 5%. Other assumptions had <10% impact on the 
projections. 
 
Discussion  
This study examines the feasibility of HCV elimination among PWID in Athens using 
an integrated healthcare strategy, which considers a scale up in both antiviral 
treatment and harm reduction coverage. Using combined interventions, the benefits 
are optimized with the expansion of harm reduction programmes acting directly to 
reduce incidence while antiviral treatment acting directly on chronic prevalence (and 
subsequently incidence) of HCV infection. Our results support current 
recommendations from WHO (13) which suggest that HCV elimination among PWID 
is possible with large increases in HCV treatment coupled with modest increases in 
harm reduction levels, even in PWID populations with very high prevalence of HCV 
infection. More specifically, elimination is achievable by 2030 under treatment 
coverage rates of more than 644 PWID/year with simultaneous annual increase of 
2% in harm reduction coverage. However, under aggressive treatment strategies 
(coverage of more than 1370 PWID/year), elimination would be possible in the next 
4-5 years. 
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Although a 2% increase in harm reduction programs may seem optimistic in the 
context of austerity in Greece, it has to be pointed out that, during the first years of 
economic crisis, the Greek Organization Against Drugs substantially increased the 
number of centers providing opioid substitution treatment by 50% during 2011-2012 
and, in cooperation with non-governmental organizations and the Hellenic Centre 
for Diseases Control and Prevention scaled up needle and syringe programmes (from 
7 to 45 syringes per estimated PWID per year between 2010 and 2012) (44). 
The assumption concerning HCV re-infection is an important part of the modeling 
procedure. In this paper, we have assumed that the risk of re-infection was equal to that 
of initial infection. Page et al (45) have shown similar incidence rates concerning initial 
infection and reinfection after spontaneous clearance. However, PWID completing 
treatment successfully may also exhibit reduced risk behavior, which would provide a 
greater prevention effect than we predict. As a result, our hypothesis of similar risk of 
infection and reinfection after treatment might be relatively conservative. 
Moreover, in our model we do not allow for re-treatment of PWID in whom 
treatment fails. Based on the assumed SVR (90%-95%), we do not anticipate this to 
have a substantial impact on our prevalence/incidence impact estimates. 
Furthermore, based on a recent review (46), next-generation DAAs are anticipated to 
reduce resistance-associated substitutions. 
Comparison with other studies 
Our results are consistent with a previous modeling analysis showing that 
combination prevention with HCV DAA therapy and harm reduction could have a 
substantial impact on chronic prevalence and incidence among PWID populations 
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(20). Importantly, this analysis explores an even higher prevalence setting than 
previously examined (64% chronic prevalence among PWID in Athens, compared to a 
maximum of 60% explored in Martin et al. (20). Notably, although our analysis may 
be seen as slightly more optimistic as we assume a long duration of participation in 
harm reduction programmes, we assume about a 60% efficacy of harm reduction 
programs in reducing an individual’s risk of acquiring HCV, whereas Martin’s analysis 
assumes approximately 50-60% on OST or HCNSP, and 80% combined. Overall, 
however, both these studies underline the significance of both expanding harm 
reduction programmes as well as ensuring PWID are retained on these interventions. 
Strengths and Limitations 
This paper is useful as it provides theoretical support that HCV elimination is possible 
under high treatment rates combined with harm reduction, even in high-prevalence 
settings like Athens. The strength of our model is that based on reliably 
epidemiological parameters which were obtained from a large sample of the PWID 
population in Athens (31, 32).   
However, our analysis has also limitations. First, the model ignores the impact of 
social networks on HCV transmission and assumes that the population is totally 
mixed i.e. injectors have equal contact with all other injectors in the population. This 
hypothesis may lead to underestimation of the forecasted reduction of prevalence 
(47). Second, the model did not take into account HCV/HIV coinfection. The effect of 
coinfection on our projections is likely to be marginal because HIV/HCV coinfected 
PWID achieve similar SVR to HCV monoinfected PWID under DAA therapy (48) and 
the additional mortality risk amongst HIV infected PWID is likely to be small, over the 
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duration of our projections, because most HIV-infected PWID were infected recently. 
A third limitation is that the model does not take into account issues related to 
identifying HCV-infected PWID.  The majority of infected PWID are undiagnosed and 
unlinked to care, so the success of treatment as prevention interventions is 
inseparable with the success of case-finding of infected PWID. Furthermore, the high 
cost of antiviral treatment today is the main barrier for increasing the coverage of 
treatment. In this paper, we have not addressed this problem since currently, there 
is a considerable uncertainty concerning cost estimations as price negotiations on 
DAAs have been initiated in Greece and the costs should reduce in the near future. 
In addition, in assessing the impact of harm reduction and HCV treatment we have 
not taken into account the different costs associated with these interventions. 
Future work examining the relative cost-effectiveness and optimal allocation from a 
budgetary standpoint is needed. The cost of treating 664 or 1370 PWID per year with 
the current prices, i.e. before negotiations, would range between 22-31 and 45-63 
million euros, respectively. Clearly, this cost is very high and underlines the need for 
negotiating to further reduce the cost of HCV care. Encouragingly, we show that 
increasing the coverage of harm reduction can reduce HCV incidence as well as the 
required treatments needed to reach a specific decline in prevalence and, thus, the 
cost of the strategies. 
Finally, the model projections are sensitive to uncertainty in a number of underlying 
parameters. Sensitivity analyses provide evidence that under shorter injecting 
durations, i.e. if the population of PWID was renewed more rapidly, the effect of 
treatments would shrink due to less time to accrue treatment benefits. On the other 
 
 
 20 
hand, if injecting duration was longer than 12 years, the impact of treatment would 
be more substantial. More accurate estimation of injecting duration would reduce 
the uncertainty in the model projections.  Our estimate of 12 years was obtained 
from a very large sample of PWID in Athens. According to data collected from PWID 
in treatment, the mean duration of injecting drug use was 10.1 years33. Adherence to 
therapy is a significant parameter that affects the efficacy of the intervention. More 
specifically, under low adherence e.g. if the assumed SVR is 80% instead of 95%, the 
impact of the intervention would be reduced by 10%. Another significant factor that 
contributes to the optimization of the intervention is any change in risk behavior 
after a successful treatment. Under the treatment as prevention strategy, treatment 
expansion to more recent PWID with higher infection risk behavior or younger PWID 
without major concerns about HCV reinfection could decrease the potential impact 
of the intervention(6, 49). Conversely, if the risk of reinfection following treatment is 
50% lower than the primary risk of infection, then the impact of the intervention 
would be substantially higher. Therefore, treatment should be coupled with risk 
reduction counseling and behavior change interventions.  
Conclusion 
 Overall, our results are based on a complex model with uncertainties concerning 
e.g. re-infection and re-treatment, new medications, possible changes in injection 
careers, network effects etc. However, in the absence of empirical data, modeling is 
useful in establishing the possibility and plausibility of the results, and indicates 
which parameters are most crucial in influencing the likely outcome. Our results, 
based on these theoretical modelling projections, show that it is plausible to observe 
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substantial reduction in HCV incidence and prevalence in the high prevalence 
population of PWID in Athens using an integrated healthcare strategy. Elimination in 
the next 4-5 years is feasible by increasing treatments rates to over 1370 PWID per 
year. Using integrated strategies, the necessary treatments to achieve specific goals 
are reduced. 
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Table 1: Model Parameters and references 
Parameter Estimate Reference 
PWID population size in Athens 
(95% CI) 
8300 
(6392-10985) 
(34) 
Anti-HCV  prevalence  among PWID 
(95% CI) 
80% 
(77.5%, 82.5%) 
(34) 
Proportion acutely infected 
spontaneously clearing infection 
20% (37) 
Duration of injecting carrier among 
PWID in Athens 
12 years (31) 
Overall PWID mortality 2% (50-52) 
Proportion of PWID at high risk (η)* 23% (31) 
Proportion participating in harm 
reduction programmes (OST or high 
coverage HCNSP) (β) 
44% (32) 
Relative risk for HCV infection for high 
risk PWID (Π) 
2.3 (31) 
Relative risk for HCV infection while in a 
harm reduction programme (Z) 
0.41 (7) 
Duration in the high risk group (12/κ) 12 months (32) 
Duration of DAA therapy (52/T) 12 weeks (40) 
Proportion achieving SVR 
IFN-free DAAs 
 
90% until 2017 
95% until 2030 
 
(41-43) 
* Defined as proportion of PWID experiencing unstable housing 
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Figure 1: Schematic outline of the mathematical model. Parameters: θ represents 
the new injectors flow rate, λi the infection rate per year which depends on PWID 
status (i.e. whether they are high risk or not and/or whether they participate in a 
harm reduction programme), C the proportion that spontaneously clear the 
infection, Θ(t) the annual treatment rate, ωi the proportion of PWID achieving SVR, 
μ1 (mortality in the population of PWID), μ2 (rate of leaving PWID population due to 
injecting cessation). Θ(t) depend on whether the injector participates in a harm 
reduction programme. 
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Figure 2: Model predictions for chronic HCV prevalence and the number of new 
infections among PWID in Athens for different annual treatment rates  (N) while 
assuming 2% annual increase in harm reduction programmes coverage (from 44% in 
2015 to 72% in 2030). The number of treated PWID per year and the corresponding 
percentage over the whole population of PWID in Athens are shown in parentheses. 
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2b.  New infections among PWID  
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Figure 3: Model predictions for chronic HCV prevalence and incident cases among 
PWID in Athens for different annual increases in harm reduction coverage and 
annual antiviral treatments rates (solid line: harm reduction coverage same as in 
2015, i.e. 44%, dotted line: increase in harm reduction coverage by 2% per year). 
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3b. New infections among PWID 
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Figure 4: The impact of combining interventions with various annual antiviral 
treatment rates and increases in harm reduction coverage to achieve fixed targets in 
the reduction of CHC prevalence (4a) or HCV incidence (4b) among PWID by 2030 
(50%, 75% or 85% reduction by 2030 compared to 2016). The bars correspond to 
scenarios of harm reduction coverage at 44%, 60% and 70% of PWID. 
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4b. New infections among PWID 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 34 
 
Figure 5: Results of one-way sensitivity analysis showing the relative difference in 
CHC prevalence projected in 2030 for varying parameters of the model compared to 
the base parameter values in Table 1. A value of zero describes no change from the 
projected CHC prevalence in 2030 compared to the base scenario. A positive or a 
negative value means that the projected CHC prevalence is lower or higher, 
respectively, compared to that projected under the base scenario. The scenario of 
332 annual antiviral treatments was used. 
 
 
